Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo

Abstract

Liposomal delivery of the glucocorticoid dexamethasone inhibits the growth of malignant bone lesions. We believe that liposomal encapsulation of dexamethasone offers a promising new treatment option for advanced, metastatic prostate cancer which supports further clinical evaluation.